MARKSANS Marksans Pharma Q3 FY26 results (Oct–Dec 2025) and concall
Marksans Pharma delivered a strong Q3 FY26, achieving record revenue of INR 754.4 crores with robust growth in the US and Australia. Profitability saw significant expansion, with gross margin at 58.1% and EBITDA margin at 21.3%, driven by favorable product mix and cost efficiencies. Despite persistent pricing pressures in the UK and EU, the company is strategically expanding its global footprint and pipeline, maintaining a debt-free balance sheet with a healthy cash position.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 9.0%, net profit up 10.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 309 | 312 | 299 | 320 | 320 +4% | 340 +9% |
| EBITDA | 63 | 60 | 52 | 70 | 72 +14% | 75 +25% |
| Net profit | 63 | 55 | 38 | 48 | 100 +59% | 61 +11% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
